Anti-EGFR antibody drug conjugates

The invention relates to an anti-EGFR antibody drug conjugate. The present invention relates to an anti-epidermal growth factor receptor (EGFR) antibody drug conjugate (ADC) that inhibits Bcl-xL; compositions and methods of using the ADCs are included. Formula (IIa), formula (IIb), and formula (IIc)...

Full description

Saved in:
Bibliographic Details
Main Authors BOGHAERT ERWIN R, SOUERS ANDREW J, PHILLIPS ANDREW C, JUDD ANDREW S, BRUNCKO MILAN
Format Patent
LanguageChinese
English
Published 05.05.2023
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The invention relates to an anti-EGFR antibody drug conjugate. The present invention relates to an anti-epidermal growth factor receptor (EGFR) antibody drug conjugate (ADC) that inhibits Bcl-xL; compositions and methods of using the ADCs are included. Formula (IIa), formula (IIb), and formula (IIc). 本发明涉及抗EGFR抗体药物偶联物。本发明涉及抑制Bcl-xL的抗表皮生长因子受体(EGFR)抗体药物偶联物(ADC)；包括组合物和使用所述ADC的方法。式(IIa)、(IIb)、(IIc)。
Bibliography:Application Number: CN202211269794